

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Cancelled).
2. (Cancelled).
3. (Cancelled).
4. (Cancelled).
5. (Cancelled).
6. (Cancelled).
7. (Cancelled).
8. (Cancelled).
9. (Cancelled).
10. (Cancelled).
11. (Cancelled).
12. (Cancelled).
13. (Cancelled).
14. (Cancelled).

15. (Cancelled).

16. (Cancelled).

17. (Cancelled).

18. (Cancelled).

19. (Cancelled).

20. (Cancelled).

21. (Cancelled).

22. (Cancelled).

23. (Cancelled).

24. (Cancelled).

25. (Cancelled).

26. (Cancelled).

27. (Cancelled).

28. (Cancelled).

29. (Cancelled).

30. (Currently Amended) A mutant antibody that comprises a mutant immunoglobulin chain, the mutant antibody having higher affinity for an antigen than a parent antibody that comprises a parent immunoglobulin chain, wherein the mutant immunoglobulin chain comprises an amino acid substitution that eliminates a variable region glycosylation site of

the parent immunoglobulin chain<sub>u</sub> said elimination having the effect of increasing the affinity of the mutant antibody relative to the parent antibody.

31. (Previously Presented) The mutant antibody of claim 30, wherein the glycosylation site is an N-linked glycosylation site selected from the group consisting of:

- (1) -Asn-X-Ser-; and
- (2) -Asn-X-Thr-;

wherein X is an amino acid other than Pro.

32. (Currently Amended) The mutant antibody of claim 30<sub>u</sub> wherein the glycosylation site is an O-linked glycosylation site selected from the group consisting of:

- (1) -Thr-X-X-Pro-; and
- (2) —Ser-X-X-Pro-;

wherein X is an amino acid.

33. (Currently Amended) The mutant antibody of claim 30<sub>u</sub> wherein the mutant antibody is a humanized version of the parent antibody.

34. (Currently Amended) The mutant antibody of claim 30<sub>u</sub> whose variable region has no glycosylation sites.

35. (Currently Amended) The mutant antibody of claim 30<sub>u</sub> whose variable region has no N-linked glycosylation sites.

36. (Currently Amended) The mutant antibody of claim 30<sub>u</sub> wherein the parent antibody is murine M195 antibody.

37. (Currently Amended) The mutant antibody of claim 30<sub>u</sub> wherein the mutant antibody is a humanized M195 antibody.

38. (Currently Amended) The mutant antibody of claim 30<sub>u</sub> wherein the antigen is a cell surface glycoprotein.

39. (Currently Amended) The mutant antibody of claim 30<sub>u</sub> wherein the mutant immunoglobulin chain is an immunoglobulin heavy chain.

40. (Currently Amended) The mutant antibody of claim 30<sub>u</sub> wherein the amino acid substitution is a conservative amino acid substitution.

41. (Currently Amended) The mutant antibody of claim 31<sub>u</sub> wherein the mutant immunoglobulin chain is an immunoglobulin heavy chain.

42. (Currently Amended) The mutant antibody of claim 31<sub>u</sub> wherein the amino acid substitution is a conservative amino acid substitution.

43. (Currently Amended) The mutant antibody of claim 32<sub>u</sub> wherein the mutant immunoglobulin chain is an immunoglobulin heavy chain.

44. (Currently Amended) The mutant antibody of claim 32<sub>u</sub> wherein the amino acid substitution is a conservative amino acid substitution.

45. (Currently Amended) The mutant antibody of claim 38<sub>u</sub> wherein the cell surface glycoprotein is the CD33 antigen.